

Date: April 22, 2015 Administrative Circular: 2015:04

**ATTN:** Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2 - Immunization Program, Section VII – Biological Products

### **Section VII - Biological Products**

# For all of the immune globulin products, the following *general* updates have been made:

Product pages re-formatted and content re-organized to be consistent across all of the immune globulin products.

Precaution related to the administration of immune globulin products to individuals with bleeding disorders revised to reflect current recommendations.


Precaution related to the administration of immune globulin products to individuals with IgA deficiency updated to include the recommendation that these products should be administered in an emergency room setting due to the increased risk of anaphylaxis.

Special consideration added related to documentation after administration of immune globulin products.

Adverse events updated.

New adverse event added: A potential increased risk of thrombosis (blood clots) has been observed within 24 hours of receipt of immune globulin products, especially when given in large doses (i.e. more than 10 mL). Additional risk factors include: age 45 years and older, history of thrombosis or those with risk factors for thrombosis (e.g., obesity, high blood pressure, diabetes, prolonged periods of immobilization, use of estrogens, a history of heart disease, blood clotting disorders, indwelling central vascular catheters, or diseases that thicken the blood).





## Product specific updates include:

### Hepatitis B Immune Globulin (HBIg)

Product names and suppliers updated. Product components added.

Special consideration added related to ordering HBIg.

Please remove page numbers: 11 - 12

Dated: April 2010

Please add new page numbers: 11, 12, 12a

Dated: April 2015

## **Immune Globulin (Ig)**

Product supplier name updated. Product components added.

### Immune Globulin Preparations (HBIg, Ig, TIg, VarIg, RabIg):


- Page reformatted but content unchanged

# Immune Globulin Preparations or Blood: Timing Intervals for Vaccines Containing Live Measles, Mumps, Rubella, or Varicella Virus:

- Table order reformatted to list standard immune globulin products, followed by specific immune globulin products and blood products.
- Cytomegalovirus immune globulin (CMVIg) added.
- Intravenous immune globulin (IVIg) and Rh immune globulin (RhIg) doses and timing intervals for live vaccine administration updated.
- Receipt of packed red blood cells and timing interval for live vaccine administration updated.
- Botulism immune globulin (BabyBIG®) dose updated.
- Footnotes updated to reflect 3 month interval between receipt of Rhlg and MMR and Varicella vaccines.

Please remove page numbers: 26 - 30 Dated: November 2010, April 2010 and January 2012 Please add new page numbers: 26, 27, 27a, 28, 29 & 30 Dated: April 2015





### Rabies Immune Globulin (Rablg)

Product components updated.

Precaution added regarding giving Rablg with caution (i.e. in an emergency room setting) if the client has a history of anaphylactic reaction following receipt of any immune globulin product or history of anaphylactic reaction to any component of HyperRAB® S/D or IMOGAM® (assess risks versus benefits).

Please remove page numbers: 53 - 54

Dated: May 2014

Please add new page numbers: 53, 54, 54a

Dated: April 2015

### **Tetanus Immune Globulin (Tlg)**

Product components added.

Precaution added regarding giving Tlg with caution (i.e. in an emergency room setting) if the client has a history of anaphylactic reaction following receipt of any immune globulin product or history of anaphylactic reaction to any component of HYPERTET® S/D (assess risks versus benefits).

#### **Tetanus Prophylaxis in Wound Management**

Table re-formatted and product specific information removed from footnotes.

Please remove page numbers: 67 - 69 Dated: April 2010 & January 2009 Please add new page numbers: 67 - 69

Dated: April 2015

#### Varicella Zoster Immune Globulin (Varlg)

Special consideration added related to ordering Varlg.

Please remove page numbers: 76 - 77


Dated: April 2010

Please add new page numbers: 76 - 77

Dated: April 2015

Please also remove the Table of Contents for Section VII – Biologicals Products dated March 2015 (2 pages) and replace with the enclosed updated Table of Contents section dated April 2015 (3 pages).





If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555, fax (604) 707-2515 or by email at Christine.halpert@bccdc.ca.

Sincerely,

Monika Naus, MD MHSc FRCPC FACPM

Medical Director

Immunization Programs and Vaccine Preventable Diseases Service

BC Centre for Disease Control

pc: BC Ministry of Health:

Dr. Perry Kendall

Provincial Health Officer

Dr. Bonnie Henry

**Deputy Provincial Health Officer** 

Dr. Evan Adams

Deputy Provincial Health Officer for Aboriginal Health

Craig Thompson

Director, CD Prevention - Immunization

Warren O'Briain

Executive Director,

Communicable Disease and Addiction Prevention



